Apexigen America, Inc.

Apexigen America, Inc. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2010-01-01
Employees
27
Market Cap
-
Website
http://www.apexigen.com

A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma

First Posted Date
2020-04-08
Last Posted Date
2024-02-13
Lead Sponsor
Apexigen America, Inc.
Target Recruit Count
45
Registration Number
NCT04337931
Locations
🇵🇱

Centrum Onkologii - Instytutu im. Marii Skłodowskiej - Curie w Warszawie, Warsaw, Poland

🇵🇱

Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu, Poznan, Poland

🇪🇸

Hospital Universitari Vall D'Hebron, Barcelona, Spain

and more 16 locations

APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

First Posted Date
2017-05-24
Last Posted Date
2024-05-02
Lead Sponsor
Apexigen America, Inc.
Target Recruit Count
34
Registration Number
NCT03165994
Locations
🇺🇸

Wake Forest School of Medicine, Winston-Salem, North Carolina, United States

🇺🇸

University of Cincinnati Medical Center, Cincinnati, Ohio, United States

🇺🇸

Renovatio Clinical, The Woodlands, Texas, United States

and more 7 locations

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

First Posted Date
2017-04-21
Last Posted Date
2023-12-26
Lead Sponsor
Apexigen America, Inc.
Target Recruit Count
140
Registration Number
NCT03123783
Locations
🇪🇸

H. Doce de Octubre, Madrid, Spain

🇪🇸

H. Vall d'Hebron, Barcelona, Spain

🇪🇸

H. Lucus Augusti, Lugo, Spain

and more 20 locations

Study of the CD40 Agonistic Monoclonal Antibody APX005M

First Posted Date
2015-06-26
Last Posted Date
2023-12-20
Lead Sponsor
Apexigen America, Inc.
Target Recruit Count
43
Registration Number
NCT02482168
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

🇺🇸

Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath